Labcorp Holdings Inc. (LH) Revenue by Segment

Labcorp revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Labcorp's largest business segment was Diagnostics, with $2.90 billion or 78% of revenue, up 5.5% from a year earlier. Next: Biopharma Laboratory Services (22%).

The fastest-growing business segment from a year earlier was Biopharma Laboratory Services (+6.5%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Labcorp Holdings Inc.

LHHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

DiagnosticsLabCorp DiagnosticsCovance Drug DevelopmentBiopharma Laboratory ServicesDrug Development

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before	Trend
Diagnostics	USD 2.90B	77.6%	+5.5%
Biopharma Laboratory Services	USD 836.20M	22.4%	+6.5%

Sum of items USD 3.74B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Diagnostics	2.9B	2.8B	2.7B	2.8B	2.7B	2.6B	2.6B	2.6B	2.5B	2.5B	2.3B	2.3B	2.3B	2.4B	–	2.2B	2.3B	2.5B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
LabCorp Diagnostics	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.6B	2.4B	2.8B	–	2.7B	1.7B	1.7B	1.8B	1.8B	1.8B	1.7B	1.7B	1.8B	1.8B	1.8B	–	1.8B
Covance Drug Development	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.5B	1.5B	1.4B	–	1.2B	1.1B	1.1B	1.2B	1.2B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	–	867.1M
Biopharma Laboratory Services	836.2M	780.6M	793.0M	799.1M	784.8M	721.3M	767.0M	737.7M	707.0M	710.9M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Drug Development	–	–	–	–	–	–	–	–	–	–	694.8M	719.1M	699.0M	661.3M	–	666.4M	677.9M	1.5B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Labcorp revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Diagnostics	$2.9B	$2.8B	$2.8B	$2.7B	78%
Biopharma Laboratory Services	$836.2M	$780.6M	$799.1M	$784.8M	22%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Labcorp's business segments?

Diagnostics and Biopharma Laboratory Services (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Labcorp?

Diagnostics: $2.90 billion, or 78% of revenue, in Q2 fiscal 2026.

MoreLabcorp stock overview Labcorp financials Labcorp executive team

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.